I Squared Capital establishes nLighten, a European edge datacenter platform
8.2.2023 16:43:00 EET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund III, has established nLighten, an edge datacenter platform dedicated to delivering solutions for both traditional and low-latency use cases. I Squared has committed more than $500 million of equity to support nLighten’s ambition to bring high quality colocation services to underserved cities and regions across Europe. nLighten is part of I Squared Capital’s global datacenter portfolio, including KIO in the Americas and BDx in Asia.
nLighten is led by former senior executives from Equinix, including Harro Beusker, Co-Founder and CEO, and Chad McCarthy, Co-Founder and CTO. Harro has held various leadership roles at Equinix, including SVP of Corporate Development for EMEA, Managing Director Germany and Netherlands and Interim Managing Director France, and Chad was most recently Equinix’s Global Head of Engineering Development and Master Planning. Both were instrumental in the development of Equinix’s business in EMEA as well as key global initiatives like its hyperscale platform, xScale. Other members of the management team include Christian Zipp, former VP of Sales of Germany and Netherlands for Digital Realty and before that Regional VP of Sales in Germany for Equinix, and Martin Essig, former MD of Telecity Germany.
nLighten’s initial focus will be in Germany, where it expects to open ten strategic locations in Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Cologne, Leipzig, Munich, Nuremberg, and Stuttgart in the second half of 2023. Through the combination of a distributed nationwide footprint and innovative connectivity partnerships, nLighten intends to offer a latency of 2 to 6 milliseconds to most 5G and last-mile users. The company is also pursuing the deployment of innovative energy solutions, including grid stabilization and the recovery and export of heat to nearby buildings and utility networks.
“With our team of experienced professionals, we are looking to create a step-change in the datacenter industry,” said Harro Beusker, CEO and Co-Founder of nLighten. “We will be close to the customer, bring connectivity ecosystems to regional markets, and actively support the energy transition.”
About nLighten
With its German headquarters in Eschborn, near Frankfurt am Main, nLighten is a digital infrastructure platform and a portfolio company of I Squared Capital. Founded in 2021 by a core team with many years of experience and wide-ranging expertise in the datacenter sector, nLighten intends to build, acquire and operate multiple edge datacenter platforms across Europe. (https://www.nlighten.eu)
nLighten acquired its initial data centers in Germany from EXA Infrastructure, another portfolio company of I Squared Capital.
About I Squared Capital
I Squared Capital is an independent global infrastructure investment manager with over $36 billion in assets under management focusing on energy, utilities, digital infrastructure, environmental infrastructure, transport and social infrastructure in North America, Europe, Latin America and Asia. The firm has offices in Miami, Hong Kong, London, New Delhi, Singapore, Taipei, and Sydney.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006198/en/
Contact information
Andreas Moon
Partner and Head of Investor Relations
I Squared Capital
andreas.moon@isquaredcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom